

22 July 2025

cGraft vs Host Disease and Associated Treatments

Q1. Within your trust, how many patients underwent allogeneic hematopoietic stem cell transplantation (HSCT) (OPCS-4 codes X33.6, X33.8, or X33.9):

- In 2023 14 patients
- In 2024 18 patients
- Between January 2025 and June 2025 <5* patients

Q2. Within your trust, of all the patients identified in Q1, how many were diagnosed with chronic graft-versus-host disease (cGvHD)*:

- In 2023 5 patients
- In 2024 <5 patients
- Between January 2025 and June 2025 <5* patients

*cGvHD will be defined as ODS-10 code D89.811 OR EITHER ODS-10 code D89.8 ≥100 days after allogeneic HSCT or ODS-10 code T86.0 ≥100 days after allogeneic HSCT.

Q3. Within your trust, how many patients are currently receiving treatment for cGvHD (as defined above) with:

- Jakavi (ruxolitinib)
- Extracorporeal photopheresis (ECP) <5* patient (transplanted onsite 2024),
 5 patients (transplanted elsewhere)
- Rezurock (belumosudil)
- Any other treatment [please state which treatments]

*Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q4. Within your trust, between January 2025 and June 2025, how many patients were initiated* on Rezurock (belumosudil)?

*Patients are considered initiated if they have not been treated with Rezurock (belumosudil) in the previous 12 months.





22 July 2025

- Q5. Within your trust, how many patients are currently receiving 400mg of Rezurock (belumosudil) daily (200mg twice daily)?
- Q6. Within your trust, since January 2024, how many patients have discontinued treatment with Rezurock (belumosudil)?
- Q7. Within your trust, what is the average duration of Rezurock (belumosudil) treatment, in months?

Q4-Q7: To detail therapy prescribed will require a manual trawl of patient records as pharmacy cannot pull this data for us. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information. A manual trawl of patient records would exceed 18 hours to complete.

Contact: publicliaison@belfasttrust.hscni.net